Sandoz

R&D

Challenges and opportunities in the off-patent sector: the p...

In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Rebecca Guntern, vice president of medicines for Europe at Sandoz.

News

Novartis takes aim at MS blockbuster Tysabri in US and Europ...

Regulators in the US and Europe have started to review Novartis' biosimilar version of Biogen's big-selling multiple sclerosis therapy Tysabri, which could reach the market next year.

News

Novartis faces tougher decision on Sandoz, as finances recov...

Novartis said this morning that it remains on course to make a decision on the future of its generics business Sandoz by the end of the year, amid signs of a "return towards normal business

News

Polpharma in pole position for biosimilar Tysabri in Europe

Polpharma Biologics has become the first company to file for approval in the EU of a biosimilar version of Biogen's blockbuster multiple sclerosis therapy

News

Sandoz, Ares extend digital alliance on antimicrobial resist...

Novartis' generics unit Sandoz has moved on to the next stage of a collaboration with Ares Genetics, which is focusing on the use of artificial intelligence to track

News

Sandoz bulks up ahead of possible sale with Coalesce buy

Novartis may be planning to sell off its generics business Sandoz, but that hasn't stopped it investing in the unit ahead of a decision on its future later this year.

Challenges and opportunities in the off-patent sector: the p...

Novartis takes aim at MS blockbuster Tysabri in US and Europ...

Novartis faces tougher decision on Sandoz, as finances recov...

Polpharma in pole position for biosimilar Tysabri in Europe

Sandoz, Ares extend digital alliance on antimicrobial resist...

Sandoz bulks up ahead of possible sale with Coalesce buy

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Sandoz

Editor's Picks